Cytokinetics, Incorporated's stock ($CYTK) has been experiencing a significant amount of implied volatility with the introduction of weekly options, as market participants anticipate a potential buyout, with the market expecting a buy-out soon. The volatility has been accompanied by notable trading volume and price spikes, particularly towards the end of the trading day (EOD). Speculation is rife that the company, currently valued at $8.5 billion, could be sold for a minimum of the $13 billion range, considering the promising data of its drug candidate, aficamten, which is seen as superior to that of the previously acquired Myokardia. Despite a premarket dip of 9% on one day due to lack of buyout news, the sentiment remains bullish, with expectations of a sale price between $135 to $150 per share, especially if there is no European and/or US deal. The CEO's demeanor in a recent interview, described as too happy and relaxed, and the absence of a capital raise following recent data releases have further fueled speculation of an imminent partnership, which could result in the stock going down, or a sale, which could drive the stock up. The Wall Street Journal reported a potential deal, which led to a 15% surge in the stock price after an earlier decline on the same day, suggesting that the bidding is only getting started.
Added more shares $CYTK https://t.co/rK3foS7Rp9
Honestly $CYTK still a good buy here, no? Seems like a 15%+ <1 month return lol
$CYTK now up 15% on deal report from WSJ, after having been down earlier in the day. #JPM24
Hit triple digits. Now the next question is deal price. $CYTK https://t.co/fUhiOMmJj0
$CYTK GO MORE BOOM https://t.co/OlealGEjhS
All the $CYTK haters take a seatπ€ @ProfessorOfETFs @monaco_biotech https://t.co/5Kb60tlBiJ
$CYTK its happening! Now WSJ! https://t.co/YABVHXiJ4u https://t.co/bIjxLXrJRH
Assuming, $CYTK is bought in the next few weeks: What price does it catch?
$cytk -9% premarket on no buyout news. If not today, I guess the bidding is only getting started following late December data release. CEO said lots of meetings at #jpm24.
$cytk got infected by FOMO today and doubled down...no raise following data either means imminent partnership (stock down) or sale (stock up)...and CEO was too happy and relaxed at the beginning of that interview... My bet: sale for $135-150 announced by Monday morning.
Spot on here $CYTK ππΌ https://t.co/ii66z7hKoW
$CYTK as long as no European and/or US deal...if it sells off on Monday on no M&A news, just hold the stock as it should find a suitor srtl. $13B Myokardia price range is minimum since #aficamten has better data. Current 8.5B MC is a safe valution IMO.
Interesting volume & spike EOD for $CYTK π https://t.co/dYKrqOMa8U
$CYTK https://t.co/sv9tXzXZiB
$CYTK now with weekly options. Lots of implied volatility for next few weeks. Market expecting a buy-out soon IMO.
$CYTK now with weekly options. Lots of implied volatility for next few weeks.